TrialESMO open2026

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial.

J Bedke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.